> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BlackRock Units Together Hold 5.3% Of Shattuck Labs, A Passive Stake Worth Watching
- URL: https://www.bullished.co/blackrock-units-together-hold-5-3-of-shattuck-labs-a-passive-stake-worth-watching-416a817a/
- Published: 2026-10-27T21:41:58.000Z
- Updated: 2026-11-05T20:03:04.000Z
- Description: BlackRock reported 5,339,458 shares of the Crohn's-focused biotech, with sole voting power over 5,221,737 of them.
- Author: Matteo Parrino
- Tags: SEC Filings, STTK, Industry: Healthcare

BlackRock says several of its business units together hold [5,339,458 shares](https://www.sec.gov/Archives/edgar/data/0002012383/000201238326003846/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Shattuck Labs](https://www.bullished.co/tag/sttk/), or 5.3% of the common stock, according to a passive ownership filing (a Schedule 13G) made Tuesday. Shattuck, a clinical-stage biotech, closed at $5.77 on Tuesday, giving it a market value of $556 million.

## Votes and the reporting units

BlackRock reported sole voting power over 5,221,737 of the shares and no shared voting power. The filing sets the event date at September 30, 2026 and classes BlackRock as a parent holding company filing on behalf of its units.

An [exhibit](https://www.sec.gov/Archives/edgar/data/2012383/000201238326003846/Item%5F7.txt?ref=bullished.co) names the units: BlackRock Advisors, BlackRock Fund Advisors, BlackRock Institutional Trust Company, BlackRock Financial Management and BlackRock Investment Management.

The filing says various persons have the right to receive dividends or sale proceeds from the stock, and that no one person's interest exceeds 5% of the outstanding shares.

## A passive holder, by certification

BlackRock certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Shattuck.

## A Crohn's drug in early testing

Shattuck, based in Austin, Texas, develops antibodies that block a protein called Death Receptor 3 to treat inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is in an early-stage trial in healthy volunteers, and the company plans a mid-stage trial in Crohn's disease patients to begin in the third quarter of 2026, it said in its annual report.

The company has no approved products and relies on a single contract manufacturer, Kemwell Biopharma, for the bulk drug substance of SL-325.

The position sits just over the 5% line that triggers a 13G filing, with the stock at $5.77 at Tuesday's close.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — BlackRock, Inc. re: SHATTUCK LABS, INC. (STTK)](https://www.sec.gov/Archives/edgar/data/0002012383/000201238326003846/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99 — EXHIBIT 99: ITEM 7](https://www.sec.gov/Archives/edgar/data/2012383/000201238326003846/Item%5F7.txt?ref=bullished.co) — SEC EDGAR

### More on Shattuck Labs

- [Shattuck Labs' Quarterly Loss Reaches $25.2 Million As Crohn's Trial Costs Climb](https://www.bullished.co/shattuck-labs-quarterly-loss-reaches-25-2-million-as-crohns-trial-costs-climb-78b6979b/)

[All Shattuck Labs (STTK) coverage →](https://www.bullished.co/tag/sttk/)